Abstract
e19093 Background: Thoracic SBRT in patients with stage IV non-small cell lung cancer (NSCLC) has the potential to improve overall survival (OS) by controlling the most likely sites of relapse and delaying disease progression, as is the case with treatment of oligometastasis. We hypothesized that thoracic control with SBRT can improve OS for select patients with stage IV NSCLC. Methods: A retrospective review was performed of all stage IV NSCLC patients treated with SBRT from January 2007 through July 2013. Patients had total of ≤ 5 sites of oligometastasis. All patients received SBRT to a thoracic site. Patients were commonly treated with a biological equivalent dose ≥ 100. Results: 23 patients were treated to a total of 30 thoracic sites with SBRT. Median age was 63 (43 – 91) and median follow up after SBRT was 12.0 months for all patients. The 1, 2 and 3 year actuarial OS rates were 86.7%, 45.7% and 22.8% respectively. Median OS was 24 months for all patients. Median survival of 8 patients who received...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call